marked.bio

KRAS G12C inhibitor (OFF state) · small molecule

glecirasib

12 active trials across 7 of our biomarkers, targeting KRAS G12C. Not approved for any biomarker on marked.bio yet.

Also known as JAB-21822.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 12 13 Phase 3
ALK fusion 1 1 Phase 2
BRAF V600E 1 1 Phase 2
EGFR exon 20 insertion 1 1 Phase 2
NTRK1/2/3 fusion 1 1 Phase 2
RET fusion or mutation 1 1 Phase 2
ROS1 fusion 1 1 Phase 2

Sponsors

Industry sponsors leading active biomarker-selected trials of glecirasib.

  1. Allist Pharmaceuticals 6
  2. Jiangsu Hengrui 1
  3. Baili-Bio / SystImmune 1
  4. Abbisko Therapeutics 1

Trials

12 of 13 trials shown

  1. A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment

    Not yet recruiting Phase 3 Jiangsu Hengrui Started 2026Primary completion 2028-05 NCT07601048

    HRS-7058fulzerasibgarsorasibglecirasib

    …enter Phase III Trial of HRS-7058 Versus the Investigator-Selected KRAS G12C Inhibitor in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Stand…

    KRAS G12CKRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment

  2. JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

    Recruiting Phase 3 Allist Pharmaceuticals Started 2024Primary completion 2029-09 NCT06416410

    glecirasibtislelizumabsitneprotafibpemetrexedcarboplatin

    G12C mutation confirmed by the central lab

    KRAS G12CAdvanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer

  3. Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC

    Not yet recruiting Phase 1/2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2026Primary completion 2027-09 NCT07339839

    glecirasibivonescimab

    KRAS G12C mutation confirmed by validated testing.

    KRAS G12CNSCLC Stage IV, KRAS G12C

  4. A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Not yet recruiting Phase 2 Baili-Bio / SystImmune Started 2026Primary completion 2028-12 NCT07827261

    izalontamab brengitecanglecirasib

    A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    KRAS G12CNon-small Cell Lung Cancer

  5. A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

    Recruiting Phase 2 Abbisko Therapeutics Started 2025Primary completion 2028-12 NCT07164170

    glecirasib

    Tumor tissue or blood test report confirmed KRASG12C mutation.

    KRAS G12CNon-Small Cell Lung Cancer

  6. Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

    Recruiting Phase 2 Sun Yat-sen University Started 2024Primary completion 2027-11 NCT06563999

    sunvozertinib FDAcrizotinibpralsetiniblarotrectinibsavolitinibpyrotinibdabrafenibtrametinibglecirasibensartinib

    Subjects should have a rare mutation based on NGS, including mutations of EGFR exon20ins, ROS1 fusion, RET fusion, NTRK fusion, MET 14 exon, HER2, BRAF V600E, KRAS G12C, and ALK …

    EGFR exon 20 insertionKRAS G12CBRAF V600EALK fusionROS1 fusionRET fusion or mutationNTRK1/2/3 fusionLung Cancer Stage III, Mutation

  7. A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

    Recruiting Phase 2 Allist Pharmaceuticals Started 2023Primary completion 2026-12 NCT06008288

    glecirasib

    Patients with the KRAS p.G12C mutation confirmed through testing using prospectively validated companion diagnostic rea…

    KRAS G12CKRAS P.G12C, Pancreatic Cancer, Solid Tumor

  8. A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

    Recruiting Phase 1/2 Allist Pharmaceuticals Started 2022Primary completion 2027-08 NCT05276726

    glecirasib

    Pathologically documented, locally-advanced or metastatic NSCLC with KRAS p.G12C mutation identified through molecular testing.

    KRAS G12CNon-small Cell Lung Cancer

  9. Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

    Recruiting Phase 1/2 Allist Pharmaceuticals Started 2022Primary completion 2027-03 NCT05288205

    glecirasibsitneprotafib

    …or cytologically confirmed locally advanced or metastatic advanced solid tumors harboring KRAS p.G12C mutation who have failed or lack standard-of-care (SOC) or are unwilling to undergo or in…

    KRAS G12CKRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma

  10. JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

    Active, not recruiting Phase 1/2 Allist Pharmaceuticals Started 2022Primary completion 2025-04 NCT05194995

    glecirasibcetuximab

    … colorectal cancer, advanced small intestinal cancer and advanced appendiceal cancer with KRAS p.G12C mutation

    KRAS G12CAdvanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer

  11. A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

    Active, not recruiting Phase 1/2 Allist Pharmaceuticals Started 2021Primary completion 2026-08 NCT05009329

    glecirasib

    Advanced (metastatic or unresectable) KRAS p.G12C mutant solid tumors, with failure or absence of standard treatment

    KRAS G12CNSCLC, Solid Tumor

  12. JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

    Active, not recruiting Phase 1 Jian Li Started 2025Primary completion 2026-03 NCT06838338

    glecirasibFOLFIRIFOLFOXbevacizumab

    KRAS G12C mutation.

    KRAS G12CColorectal Cancer